Neuronostics Named Most Transformative HealthTech Company at OBN Awards

Bristol-based digital health company Neuronostics has been awarded Most Transformative HealthTech Company of the Year at the prestigious OBN Awards 2025, held at the Royal Lancaster London on 26 November. 

The OBN Awards, now in their 17th year, are a highly regarded awards programme for the life sciences industry, designed to celebrate innovation and outstanding achievement. An independent panel of expert judges selected winners across twelve categories recognising companies delivering real-world impact. 

The award recognises Neuronostics’ work transforming epilepsy care through BioEP™, its patented digital biomarker. By analysing background EEG data that are not routinely used in current pathways, BioEP provides clinicians with additional objective information to support diagnostic decision-making in people with suspected epilepsy.  

“We are honoured to receive this recognition,” said Anne Hyland, Chair of Neuronostics. “BioEP builds on what clinicians already use, evolving the traditional EEG whilst significantly reducing its limitations. By providing clinicians with clearer, data-driven insight alongside routine EEG, we help strengthen the diagnostic pathway and support more informed care. When the right tools are in place, lives change, and this award is testimony to that.” 

The recognition follows a year of significant milestones, including the company’s strategic partnership with Stratus, America’s leading EEG services provider, and winning the US Epilepsy Foundation’s Shark Tank Competition. With regulatory approval in the UK and a MoHAP medical device classification enabling procurement in the UAE, Neuronostics is working towards regulatory approval in the USA and other territories.